Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Assembly Biosciences (ASMB) Stock Price & Analysis

590 Followers

ASMB Stock Chart & Stats

$22.37$1.02(4.78%)
At close: 4:00 PM EST
$20$25$30$35Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$21.00 - $22.69
52-Week Range
$19.20 - $39.71
Previous Close
$21.35
Volume
N/A
Average Volume (3M)
238.46K
Market Cap
$434.70M
Enterprise Value
$200.09M
Total Cash (Recent Filing)
$320.36M
Total Debt (Recent Filing)
$2.35M
Price to Earnings (P/E)
38.8
Beta
1.38
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Scale And Gross Margin

Material revenue expansion and a strong gross margin indicate that the company has generated meaningful commercial-scale economics relative to its prior base. If sustained, this combination can support continued investment in the antiviral pipeline and improve operating leverage as development activities progress.

Low Leverage And Financial Flexibility

Very low debt relative to equity limits debt-related pressure and preserves financial flexibility for research, clinical development, and other corporate priorities. The expanded equity base and assets also provide a stronger capitalization platform than a highly leveraged development-stage biotechnology business.

Proprietary Oral Antiviral Pipeline

A proprietary pipeline of orally available small-molecule antivirals gives Assembly a focused product-development strategy and a differentiated route to address chronic HBV. Successful advancement could create durable value from internally developed assets rather than relying only on commercialization of external products.

Bears Say

Persistent Cash Burn

Materially negative operating and free cash flow shows that the business is not yet self-funding its activities. Continued cash burn can constrain the pace of research and clinical development and may require future financing or other capital actions to sustain operations.

Negative Operating Profitability

Near-breakeven net income has not yet translated into positive operating profitability, indicating that the underlying business still lacks a consistently profitable operating model. Persistent losses at this level can limit reinvestment capacity and make earnings outcomes difficult to forecast.

Clinical-stage Commercialization Risk

Because Assembly remains clinical-stage and does not commercialize approved products, its future depends on advancing drug candidates through development. This creates a structurally uncertain path to recurring product revenue, with business value tied to successful pipeline execution.

Assembly Biosciences News

ASMB FAQ

What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $19.20 and its highest was $39.71 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $434.70M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s next earnings report is estimated for Nov 11, 2026 (not yet confirmed), which is 1 day ago.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Aug 13, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.724 by $0.524.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.66.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 20,360,596 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.724. Following the earnings report the stock price went up 4.778%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Hedge funds hold Assembly Biosciences shares: the largest hedge-fund position in Assembly Biosciences is 70,130,375 shares, and hedge funds increased their holdings by 940.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology